Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/28/2025

Weight Loss with Tirzepatide and Semaglutide

Comparative Efficacy for Weight Loss

  • The American Medical Association recommends tirzepatide for weight loss, as it demonstrates significantly greater weight reduction effects compared to semaglutide, with mean weight loss of up to 21% at 72 weeks versus 15% with semaglutide 1, 2
  • Tirzepatide has demonstrated the greatest weight loss effect among FDA-approved medications for weight management, with mean weight loss of 21% at 72 weeks 1, 2
  • Semaglutide (Ozempic/Wegovy) produces approximately 15% weight loss at comparable timepoints 1
  • In the SURMOUNT-1 trial, tirzepatide showed a dose-dependent weight-loss benefit with mean weight change of up to -20.9% compared with placebo in adults without diabetes over 72 weeks 3

Mechanism of Action Differences

  • Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, providing a dual mechanism of action 2, 4
  • Semaglutide is solely a GLP-1 receptor agonist 4
  • The dual-receptor targeting by tirzepatide likely explains its enhanced weight loss efficacy compared to single-receptor GLP-1 agonists 2

Safety Profile Considerations

  • Common adverse effects of tirzepatide and semaglutide include nausea, diarrhea, vomiting, and constipation 5
  • Starting at a low dose and gradually titrating upward can help minimize gastrointestinal side effects 5

Weight Maintenance Considerations

  • Long-term use of these medications is important for weight maintenance, as recommended by the American Medical Association 2
  • Clinical guidelines support the use of long-term anti-obesity medications when weight maintenance is inadequate with lifestyle interventions alone 2

Dosing and Administration

  • Tirzepatide is administered subcutaneously once weekly, with a starting dose that should be low and gradually titrated to minimize side effects 4, 5
  • Regular monitoring is recommended at least monthly for the first 3 months and quarterly thereafter, as suggested by the American Diabetes Association 6

Algorithm for Decision-Making

  • If weight loss is <5% after 3 months of maximum tolerated dose of semaglutide, consider switching to tirzepatide, as recommended by the American Diabetes Association 6
  • For patients with cardiovascular disease, both medications have demonstrated cardiovascular benefits, according to the European Heart Journal 3, 5

Important Caveats

  • Comprehensive approach including dietary changes and physical activity should continue alongside medication therapy, as recommended by the American Medical Association 1, 2
  • Early response (typically defined as >5% weight loss after 3 months) predicts better long-term outcomes, according to the American Diabetes Association 6